Celladon's Series C - II Round

Celladon raised a round of funding on September 18, 2009.

Celladon is a biotechnology company developing molecular therapies for the treatment of heart failure. The company's products target the key enzyme deficiency in advanced heart failure, SERCA2a, which…

Articles about Celladon's Series C - II Round: